SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids
COVID-19; SARS-CoV-2; chronic kidney disease; fibrosis; human iPSC kidney organoids; kidney injury; protease blocker.- Cell Stem Cell
- 20.4
- 2022 Feb 3;29(2):217-231.e8.
- Human
- 单细胞测序
- 免疫/内分泌
- Cells;Nuclei from Kidney
- 免疫/内分泌
- DOI: 10.1016/j.stem.2021.12.010
Abstract
Kidney failure is frequently observed during and after COVID-19, but it remains elusive whether this is a direct effect of the virus. Here, we report that SARS-CoV-2 directly infects kidney cells and is associated with increased tubule-interstitial kidney fibrosis in patient autopsy samples. To study direct effects of the virus on the kidney independent of systemic effects of COVID-19, we infected human-induced pluripotent stem-cell-derived kidney organoids with SARS-CoV-2. Single-cell RNA sequencing indicated injury and dedifferentiation of infected cells with activation of profibrotic signaling pathways. Importantly, SARS-CoV-2 infection also led to increased collagen 1 protein expression in organoids. A SARS-CoV-2 protease inhibitor was able to ameliorate the infection of kidney cells by SARS-CoV-2. Our results suggest that SARS-CoV-2 can directly infect kidney cells and induce cell injury with subsequent fibrosis. These data could explain both acute kidney injury in COVID-19 patients and the development of chronic kidney disease in long COVID. Keywords: COVID-19; SARS-CoV-2; chronic kidney disease; fibrosis; human iPSC kidney organoids; kidney injury; protease blocker.
金课堂之文献解析 文献原文请点击
本网站销售的所有产品及服务均不得用于人类或动物之临床诊断或治疗,仅可用于工业或者科研等非医疗目的。



沪公网安备31011502400759号
营业执照(三证合一)